Immunomodulatory oligosaccharides for the treatment of pain
Alexander Martinez, Des Moines, WA (US); and Jason Ferrone, Fallbrook, CA (US)
Assigned to Intrinsic Medicine, Inc., Seattle, WA (US)
Appl. No. 17/606,149
Filed by Intrinsic Medicine, Inc., Des Moines, WA (US)
PCT Filed Mar. 25, 2020, PCT No. PCT/US2020/024621 § 371(c)(1), (2) Date Oct. 25, 2021, PCT Pub. No. WO2020/210027, PCT Pub. Date Oct. 15, 2020.
Claims priority of provisional application 62/931,386, filed on Nov. 6, 2019.
Claims priority of provisional application 62/831,245, filed on Apr. 9, 2019.
Prior Publication US 2022/0193099 A1, Jun. 23, 2022
Int. Cl. A61K 31/702 (2006.01)
CPC A61K 31/702 (2013.01)
19 Claims
1. A method of treating inflammatory pain in a patient contraindicated for non-steroidal anti-inflammatory drugs (NSAIDs), comprising administering an effective amount of sialyllactose.